ORBIMED ADVISORS LLC 13D and 13G filings for Mereo BioPharma Group plc:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 6:51 pm Sale |
2023-12-31 | 13G | Mereo BioPharma Group plc MREO |
ORBIMED ADVISORS LLC | 0 0.000% |
-10,378,591 (Position Closed) |
Filing |
| 2023-02-14 4:40 pm Purchase |
2022-12-31 | 13G | Mereo BioPharma Group plc MREO |
ORBIMED ADVISORS LLC | 10,378,591 5.920% |
4,315,246 (+71.17%) |
Filing |
| 2022-02-11 4:31 pm Purchase |
2021-12-31 | 13G | Mereo BioPharma Group plc MREO |
ORBIMED ADVISORS LLC | 6,063,345 5.590% |
1,544,989 (+34.19%) |
Filing |
| 2021-02-12 5:00 pm Purchase |
2020-12-31 | 13G | Mereo BioPharma Group plc MREO |
ORBIMED ADVISORS LLC | 4,518,356 6.660% |
4,518,356 (New Position) |
Filing |